Atogepant for Treatment-Refractory Episodic Migraine

Episodic migraine is defined by the International Classification of Headache Disorders Third Edition as having fewer than 15 headache days per month. Preventive migraine therapy is recommended in patients with disabling migraine that occurs at least 2 days per month despite the use of acute medication. Conventional oral preventive medications from classes such as beta-blockers, calcium-channel blockers, antiepileptic drugs, and antidepressants display moderate efficacy against migraine, often with poor tolerability.

In an industry-funded, multicenter, randomized, double-blind, placebo-controlled study, atogepant, an oral high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, was investigated as a preventive treatment of ep…